{
    "title": "Biogen's 2022 outlook leaves investors wanting, shares slip",
    "url": "https://www.dailymail.co.uk/wires/ap/article-10472833/Biogens-2022-outlook-leaves-investors-wanting-shares-slip.html",
    "date": "2022-02-03",
    "keywords": [
        "biogen",
        "treatment",
        "drug",
        "coverage",
        "decision",
        "year",
        "price",
        "company",
        "medicare",
        "thursday",
        "study",
        "aduhelm",
        "breakthrough",
        "drugmaker",
        "forecast",
        "cambridge",
        "research",
        "inc",
        "government",
        "population",
        "plan",
        "quarter",
        "revenue",
        "criticism",
        "debut",
        "massachusetts",
        "market",
        "june",
        "pushback",
        "insurance",
        "brain",
        "plaque",
        "role",
        "development",
        "country",
        "headquarters",
        "mass",
        "file",
        "month",
        "medicaid",
        "effectiveness",
        "order",
        "cost",
        "april",
        "feedback",
        "class",
        "ceo",
        "michel",
        "vountasos",
        "co",
        "mizuho",
        "analyst",
        "note",
        "share",
        "decline",
        "sclerosis",
        "tecfidera",
        "competition",
        "drop",
        "morning",
        "stock",
        "value",
        "tom",
        "murphy",
        "twitter",
        "thpmurphy"
    ],
    "category": [
        "wires",
        "ap"
    ]
}